采用衰弱筛查决定血液透析通路建立方式
单中心前瞻性队列研究纳入2021年4月至2023年5月期间接受新动静脉通路手术的40例患者,术前以PRISMA-7问卷评估衰弱。衰弱组(PRISMA-7评分≥3,占53%)通路失败率为48%(10/21),非衰弱组为5%(1/19)(P=0.012);多变量分析显示衰弱与非成熟显著相关(调整OR 10.19,95%CI 1.20-82.25,P=0.033)。
要点
- 衰弱组(PRISMA-7≥3)新动静脉通路失败率为48%(10/21),非衰弱组为5%(1/19)(P=0.012)。
- 衰弱组动静脉瘘未成熟率为60%(9/15),非衰弱组瘘均成熟可用(P=0.049)。
- 多变量分析显示衰弱与非成熟显著相关(调整OR 10.19,95%CI 1.20-82.25,P=0.033)。
核心结论
- 患者衰弱与动静脉通路成熟失败发生率增加显著相关。
研究设计与样本
- 单中心前瞻性队列研究,纳入2021年4月至2023年5月期间接受新动静脉瘘或动静脉移植物手术的患者,术前以PRISMA-7衰弱问卷评估,共40例。
主要发现
- 衰弱组(PRISMA-7评分≥3,占53%)动静脉通路(动静脉瘘与动静脉移植物合计)失败率为48%(10/21),非衰弱组为5%(1/19)(P=0.012)。
- 衰弱组动静脉瘘未成熟率为60%(9/15),非衰弱组动静脉瘘均成熟至可用(P=0.049)。
- 手术部位感染在衰弱组为0例,非衰弱组为5%(1/19);衰弱组30天和60天再入院率均高于非衰弱组。
- 180天死亡率在衰弱组为5%(1/21),非衰弱组为0例。
- 多变量分析显示衰弱(调整OR 10.19,95%CI 1.20-82.25,P=0.033)和较年轻年龄(调整OR 0.953,95%CI 0.923-0.983,P=0.002)均与非成熟显著相关;功效分析显示统计功效为0.898,2型错误概率为10.02%,P=0.002;Hosmer-Lemeshow拟合优度显示模型总体准确率为75%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Choosing the right hemodialysis vascular access for frail patients remains difficult because the patient's preferences and the likelihood of access function and survival must be considered. We hypothesize that patients identified before arteriovenous (AV) access as frail by the PRISMA-7 score may have worse outcomes, indicating that fistula creation may not be the most clinically beneficial option and it would be in the best interest of the patient to receive either AV graft (AVG) placement or dialysis through a percutaneous catheter. Our pilot study aims to determine whether an association exists between patient frailty as defined by PRISMA-7 and newly created AV fistula (AVF) and AVG access outcomes. METHODS: This was a single institutional prospective cohort study of patients undergoing new AVF or AVG intervention from April 2021 to May 2023. Patients were assessed using the PRISMA-7 frailty questionnaire before their AV access surgery. Patients were grouped by frailty score and score groups were examined for trends. Univariable analysis was performed for baseline differences between frail and nonfrail patients. Failure to achieve maturation, postoperative infection, and 180-day mortality difference was also investigated for frail vs nonfrail patients. Univariable analysis was performed for nonmaturation using standard comorbidities, arterial and venous diameters, and frailty. Multivariable binary logistic regression was performed for the outcome of nonmaturation using frailty as one of the variables in conjunction with the univariable risks associated with nonmaturation. RESULTS: A total of 40 patients undergoing new AV access placement were investigated, among whom 53% were designated as frail (PRISMA-7 score ≥3). When comparing the frail and nonfrail new AV access groups, the access (AVF and AVG combined) failed in 48% (10/21) of the frail patients, but only failed in 5% (1/19) of the nonfrail patients 1 (P = .012). When distinguishing between AV access types, AVF creations followed the overall trend with 60% of AVF access (9/15) sites in frail patients failing to mature when compared with nonfrail patients, who all had fistulas that matured to use (P = .049). Surgical site infection was absent in all frail patients and present in 5% of nonfrail patients (1/19). Both 30-day and 60-day readmission rates were higher in the frail group compared with the nonfrail group. There was 180-day mortality present in 5 of frail patients % (1/21) and absent in nonfrail patients. Multivariable analysis revealed that both frailty (adjusted odd ratio, 10.19; 95% confidence interval, 1.20-82.25); P = .033) and younger age (adjusted odd ratio, 0.953; 95% confidence interval, 0.923-0.983; P = .002) both had a significant association with nonmaturation. Power analysis revealed a power statistic of 0.898 indicating a probability of type 2 error of 10.02% with a P value of .002. Hosmer-Lemeshow goodness of fit for the logistic regression had 75% overall accuracy for the model. CONCLUSIONS: Patient frailty is significantly associated with an increased incidence of AV access failure to mature.
引用
- McDonnell SM, Nikfar S, Blecha M, et al. Frailty screening for determination of hemodialysis access placement. J Vasc Surg. 2023. PMID: 38104675. doi:10.1016/j.jvs.2023.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。